Published in Cancer Res on August 15, 2004
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev (2007) 1.81
Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res (2010) 1.77
Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol Syst Biol (2011) 1.65
The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. Proc Natl Acad Sci U S A (2008) 1.42
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 1.39
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation. Cancer Res (2009) 1.05
Deletion of PTENP1 pseudogene in human melanoma. J Invest Dermatol (2011) 1.00
Sprouty2-mediated inhibition of fibroblast growth factor signaling is modulated by the protein kinase DYRK1A. Mol Cell Biol (2008) 0.97
The developing story of Sprouty and cancer. Cancer Metastasis Rev (2014) 0.96
Transcriptome profile of Trypanosoma cruzi-infected cells: simultaneous up- and down-regulation of proliferation inhibitors and promoters. Parasitol Res (2007) 0.95
Looking at cerebellar malformations through text-mined interactomes of mice and humans. PLoS Comput Biol (2009) 0.95
Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget (2012) 0.94
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One (2013) 0.90
ErbB2 stabilizes epidermal growth factor receptor (EGFR) expression via Erk and Sprouty2 in extracellular matrix-detached cells. J Biol Chem (2010) 0.89
Distinct MHC gene expression patterns during progression of melanoma. Genes Chromosomes Cancer (2010) 0.86
Targeting oncogenic BRAF in human cancer. Curr Top Microbiol Immunol (2012) 0.86
Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines. J Oncol (2012) 0.83
Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v-Raf murine sarcoma viral oncogene homolog B1 (BRAF). J Biol Chem (2012) 0.82
Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field. Biomark Insights (2007) 0.82
Genes with relevance for early to late progression of colon carcinoma based on combined genomic and transcriptomic information from the same patients. Cancer Inform (2010) 0.80
Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Biochem Pharmacol (2014) 0.78
Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL. Blood (2016) 0.78
ERK and JNK activation is essential for oncogenic transformation by v-Rel. Oncogene (2010) 0.77
SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150. Oncogene (2015) 0.76
Fibrosis in the lens. Sprouty regulation of TGFβ-signaling prevents lens EMT leading to cataract. Exp Eye Res (2015) 0.76
A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy. Eur J Hum Genet (2015) 0.75
Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses. BMC Cancer (2014) 0.75
Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition. EMBO J (2017) 0.75
Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations. Int J Mol Sci (2017) 0.75
Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells. Biomol Ther (Seoul) (2015) 0.75
MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma. Am J Dermatopathol (2015) 0.75
Combined BRAF(V600E) and MEK blockade for BRAF(V600E)-mutant gliomas. J Neurooncol (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet (2003) 5.16
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity (2013) 4.08
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
Breast and ovarian cancer. N Engl J Med (2003) 3.84
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst (2002) 3.65
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res (2006) 3.21
Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell (2011) 3.19
Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol (2005) 3.14
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med (2004) 3.10
Dynamic regulatory network controlling TH17 cell differentiation. Nature (2013) 3.07
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev Cell (2005) 2.95
High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res (2005) 2.72
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
A comparison of DNA copy number profiling platforms. Cancer Res (2007) 2.63
Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell (2003) 2.61
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
LIM kinases: function, regulation and association with human disease. J Mol Med (Berl) (2007) 2.26
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res (2002) 2.25
RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol (2004) 2.24
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
The WAVE2 complex regulates actin cytoskeletal reorganization and CRAC-mediated calcium entry during T cell activation. Curr Biol (2006) 2.20
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell (2003) 2.20
Application of breast cancer risk prediction models in clinical practice. J Clin Oncol (2003) 2.19
Sprouty1 regulates reversible quiescence of a self-renewing adult muscle stem cell pool during regeneration. Cell Stem Cell (2010) 2.03
HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest (2010) 2.00
Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol (2003) 2.00
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res (2008) 1.99
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med (2007) 1.94
1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res (2003) 1.90
Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci U S A (2006) 1.87
Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res (2004) 1.84
Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Res (2004) 1.81
Ret-dependent cell rearrangements in the Wolffian duct epithelium initiate ureteric bud morphogenesis. Dev Cell (2009) 1.81
Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res (2005) 1.80
LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J Cell Biol (2010) 1.79
miR-27b controls venous specification and tip cell fate. Blood (2011) 1.79
Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest (2012) 1.73
CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol (2004) 1.72
Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci (2009) 1.71
Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol Cell Biol (2002) 1.70
Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res (2006) 1.70
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med (2012) 1.69
Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep (2012) 1.66
F-actin polymerization and retrograde flow drive sustained PLCγ1 signaling during T cell activation. J Cell Biol (2012) 1.64
The hypoxia-inducible transcription factor pathway regulates oxygen sensing in the simplest animal, Trichoplax adhaerens. EMBO Rep (2010) 1.62
Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1. Dev Biol (2006) 1.61
Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol (2003) 1.61
The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol (2006) 1.59
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet (2003) 1.58
Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology (2002) 1.58
Survivin is not required for the endomitotic cell cycle of megakaryocytes. Blood (2009) 1.57
Computerized analysis of mammographic parenchymal patterns for assessing breast cancer risk: effect of ROI size and location. Med Phys (2004) 1.57
Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J (2003) 1.55
BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell (2003) 1.55
Keratinocyte differentiation is regulated by the Rho and ROCK signaling pathway. Curr Biol (2003) 1.54
The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol Cell (2013) 1.54
Actin-myosin-based contraction is responsible for apoptotic nuclear disintegration. J Cell Biol (2005) 1.49
Extracellular ATP causes ROCK I-dependent bleb formation in P2X7-transfected HEK293 cells. Mol Biol Cell (2003) 1.49
Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res (2007) 1.48
The c-Abl tyrosine kinase regulates actin remodeling at the immune synapse. Blood (2008) 1.48
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer (2005) 1.47
Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test (2008) 1.46
PHF8, a gene associated with cleft lip/palate and mental retardation, encodes for an Nepsilon-dimethyl lysine demethylase. Hum Mol Genet (2009) 1.44
Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. Cancer Res (2011) 1.44
Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov (2012) 1.43
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol (2006) 1.41
Kidney development in the absence of Gdnf and Spry1 requires Fgf10. PLoS Genet (2010) 1.40
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol (2008) 1.37
Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res (2005) 1.37